These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2970855)

  • 1. Effects of fosenopril, a once-daily angiotensin-converting enzyme inhibitor, on resting and exercise-induced changes of blood pressure, hormonal variables, and plasma potassium in essential hypertension.
    Sullivan PA; Dineen M; Cervenka J; O'Connor DT
    Am J Hypertens; 1988 Jul; 1(3 Pt 3):280S-283S. PubMed ID: 2970855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fosenopril, an angiotensin-converting enzyme inhibitor, and propranolol: comparative effects at rest and exercise on blood pressure, hormonal variables, and plasma potassium in essential hypertension.
    Sullivan PA; Cervenka J; O'Connor DT; Dineen M
    Cardiovasc Drugs Ther; 1989 Mar; 3(1):57-62. PubMed ID: 2535052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal changes in atrial natriuretic factor and aldosterone during angiotensin converting enzyme inhibition in man.
    Sala C; Bragato R; Ardeleani G; Pulzzani E; Morganti A; Zanchetti A
    J Hypertens Suppl; 1989 Dec; 7(6):S240-1. PubMed ID: 2534410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of fosinopril and hydrochlorothiazide in patients with mild to moderate hypertension.
    Forslund T; Franzén P; Backman R
    J Intern Med; 1991 Dec; 230(6):511-7. PubMed ID: 1836220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of drug-resistant hypertension with minoxidil or angiotensin-converting enzyme inhibitor: blood pressure, renin, aldosterone, and electrolyte responses.
    Baer L; Radichevich I; Williams GS
    J Cardiovasc Pharmacol; 1980; 2 Suppl 2():S206-16. PubMed ID: 6156357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of fosinopril on cardiac function in patients with hypertension. Radionuclide assessment of left ventricular systolic and diastolic performance.
    Zusman RM; Christensen DM; Higgins J; Boucher CA
    Am J Hypertens; 1992 Apr; 5(4 Pt 1):219-23. PubMed ID: 1534664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects.
    Lewis RA; Baker KM; Ayers CR; Weaver BA; Lehman MR
    J Cardiovasc Pharmacol; 1985; 7 Suppl 1():S12-5. PubMed ID: 2580164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension.
    Santoro D; Natali A; Palombo C; Brandi LS; Piatti M; Ghione S; Ferrannini E
    Hypertension; 1992 Aug; 20(2):181-91. PubMed ID: 1639459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of angiotensin-converting enzyme inhibition on plasma aldosterone concentration, plasma renin activity, and blood pressure in spontaneously hypertensive cats with chronic renal disease.
    Steele JL; Henik RA; Stepien RL
    Vet Ther; 2002; 3(2):157-66. PubMed ID: 19750747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enalapril versus combined enalapril and nadolol treatment: effects on blood pressure, heart rate, humoral variables, and plasma potassium at rest and during exercise in hypertensive patients.
    Sullivan PA; Daly B; O'Connor R
    Cardiovasc Drugs Ther; 1992 Jun; 6(3):261-5. PubMed ID: 1637731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man.
    Gavras H; Brunner HR; Turini GA; Kershaw GR; Tifft CP; Cuttelod S; Gavras I; Vukovich RA; McKinstry DN
    N Engl J Med; 1978 May; 298(18):991-5. PubMed ID: 205788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, safety, and pharmacologic effects of fosinopril sodium, an angiotensin-converting enzyme inhibitor in healthy subjects.
    Duchin KL; Waclawski AP; Tu JI; Manning J; Frantz M; Willard DA
    J Clin Pharmacol; 1991 Jan; 31(1):58-64. PubMed ID: 1646240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the combination of cilazapril and propranolol lower blood pressure at rest and during exercise more pronouncedly than either of the two components given alone?
    Erb KA; Breithaupt K; Kleinbloesem CH; Wolf GK; Belz GG
    Clin Physiol Biochem; 1990; 8 Suppl 2():35-45. PubMed ID: 2151315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of enalapril maleate on blood pressure, renin-angiotensin-aldosterone system, and peripheral sympathetic activity in essential hypertension.
    Cerasola G; Cottone S; D'Ignoto G; Grasso L; Carone MB; Carapelle E; Contorno A
    Clin Ther; 1987; 9(4):390-9. PubMed ID: 3038326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
    Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
    Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition.
    Atkinson AB; Morton JJ; Brown JJ; Davies DL; Fraser R; Kelly P; Leckie B; Lever AF; Robertson JI
    Br Heart J; 1980 Sep; 44(3):290-6. PubMed ID: 7000102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orally active angiotensin-converting enzyme inhibitor (SO 14,225) as a treatment for essential hypertension.
    Brunner HR; Gavras H; Waeber B; Turini GA; McKinstry DN; Vukovich RA; Gavras I
    Br J Clin Pharmacol; 1979; 7 Suppl 2(Suppl 2):205S-211S. PubMed ID: 223614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Captopril in primary hypertension. Effects related to the renin-angiotensin-aldosterone and kallikrein-kinin systems.
    Ohman KP; Karlberg BE; Nilsson OR; Wettre S
    Acta Med Scand Suppl; 1981; 646():98-105. PubMed ID: 7018190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Humoral effects of the oral converting-enzyme inhibitor SQ 14,225 in hypertensive patients in supine and tilted position.
    Morganti A; Pickering TG; Lopez-Ovejero J; Laragh JH
    Clin Sci (Lond); 1979 Dec; 57 Suppl 5():149s-152s. PubMed ID: 232018
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.